MedImmune Collaborates with Johns Hopkins University - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MedImmune Collaborates with Johns Hopkins University


MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University entered into a five-year, $6.5 million research collaboration, according to a joint press release. The joint research projects will focus on MedImmune’s therapeutic areas of interest, including cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; infectious disease; and neuroscience. This new collaboration model extends to both MedImmune’s biologics and AstraZeneca’s small molecule portfolios.  

In oncology, research will explore the role of immune system cells in tumor growth and harness findings to identify new cancer drug targets. In the areas of respiratory, inflammation, and autoimmunity, projects will research the damaging mechanisms underlying rheumatoid arthritis (RA) and validate potential therapeutic targets that may play key roles in the development or progression of RA. In infectious disease, projects will assess monoclonal antibody combinations to aid in clinical candidate selections to more effectively prevent recurrent infections in high-risk patients, such as those with diabetes. This collaboration builds on MedImmune’s ongoing work to prevent serious and costly drug-resistant infections. In antibody discovery and protein engineering, MedImmune will work with the university to find innovative ways to manufacture complex next generation biologic drugs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here